Author

F. Genovese

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

The antifibrotic effect of empagliflozin: Insights from the EMPIRE trial programme

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are foundational in treating patients with heart failure (HF), type 2 diabetes (T2D), and chronic kidney disease (CKD). One proposed mechanism behind the clinical effect is attenuation of fibrotic pathways. However, clinical data to support this mechanism are lac...

J. Jensen, C. Andersen, M. Omar et al. · European Heart Journal · 0 citations

Open access Aug 2026

Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes.

In people with T2D receiving combination therapy with RASi + GLP-1 RA, urinary C3M levels remained stable, whereas levels decreased with RASi monotherapy, suggesting altered kidney ECM turnover.

A. Møller, Stefanie Thöni, Felix Keller et al. · American Journal of Physiolo... · 0 citations